Knowledge Assessment of Women About Pictograms Associated With the Danger of Medicines Taken During Pregnancy (ECOFP)
Knowledge Assessment of Pregnant or Childbearing Age Women About Pictograms Associated With the Danger of Certain Medicines Taken During Pregnancy.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Valerie Gras-Champel, MD
- Phone Number: (33)322087096
- Email: gras.valerie@chu-amiens.fr
Study Locations
-
-
-
Amiens, France, 80000
- CHU Amiens
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- women who agree to participate to the study
- women who understand french language (oral and written)
- pregnant women and women of childbearing age from 18 to 45 years old.
Exclusion Criteria:
- Women who have already answered the questionnaire
- women who don't want to answer the questionnaire
- women who don't understand french language
- women who are under the age of 18 or over the age of 45
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
pregnant women
Pregnant women are coming to their monthly consultation. A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators. Pregnant women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally. |
A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators. Women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally. |
|
childbearing age women
Women of childbearing age, who are coming for a gynecological consultation. A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators. Childbearing age women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally. |
A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators. Women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Medication pictogram women knowledge measure
Time Frame: day 0
|
Determination of women knowledge about pictograms associated with the danger of certain medicines during pregnancy by analysing the questionnaire responses
|
day 0
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Medication pictogram women information measure
Time Frame: day 0
|
Determination of women information about pictograms associated with the danger of certain medicines during pregnancy by analysing the questionnaire responses
|
day 0
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Alice Rousseaux, CH Hirson
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- PI2018_843_0042
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy Related
-
NCT06492889Not yet recruitingPregnancy Related | Pregnancy Early
-
NCT04714905CompletedPregnancy Related | Wearables | Pregnancy Early
-
NCT03737279CompletedPregnancy Related | Pregnancy, High Risk
-
NCT03403543UnknownPregnancy | Pregnancy Related | Infant | Pregnancy Disease | Risk Factor
-
NCT04693572UnknownPregnancy Related | Pregnancy, High Risk | Anesthesia
-
NCT07611175RecruitingPregnancy Related
-
NCT07331909Not yet recruitingPregnancy Related
Clinical Trials on questionary
-
NCT04881695Not yet recruitingPremature Ovarian Failure (POF)
-
NCT02805803Recruiting
-
NCT05932953RecruitingDiabetes Mellitus, Type 1 | Atopic Disorders | Cutaneous Allergy
-
NCT05850442CompletedDepressive Disorder | Anxiety Disorders | Fibromyalgia Syndrome
-
NCT05765799RecruitingPatient Satisfaction
-
NCT02570594Completed
-
NCT06666543Completed
-
NCT06400758Completed
-
NCT04277832CompletedPsoriasis | Psoriatic Arthritis